| 1 |
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial
Sebastian Stintzing et al. · The Lancet Oncology
|
2 Sep 2016 |
424 |
| 2 |
Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial
Volker Kunzmann et al. · The Lancet. Gastroenterology & hepatology
|
17 Dec 2020 |
207 |
| 3 |
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial
Sebastian Stintzing et al. · Annals of Oncology
Open access |
Nov 2019 |
198 |
| 4 |
FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109)
Dominik Paul Modest, Uwe M. Martens, Jorge Riera‐Knorrenschild et al. · Journal of Clinical Oncology
|
14 Oct 2019 |
198 |
| 5 |
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial
Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas W. Decker et al. · British Journal of Cancer
Open access |
6 Nov 2020 |
194 |
| 6 |
Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)—a randomized phase II trial of the AIO pancreatic cancer group
Thomas Theodor Werner Seufferlein et al. · Annals of Oncology
Open access |
6 Oct 2022 |
168 |
| 7 |
The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use
Wolfgang EIERMANN, Mahdi Rezai, Sherko Kümmel et al. · Annals of Oncology
Open access |
8 Nov 2012 |
147 |
| 8 |
Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study
Sebastian Stintzing, Lisa Miller‐Phillips, Dominik Paul Modest et al. · European Journal of Cancer
|
29 Apr 2017 |
139 |
| 9 |
Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial
Jobst Christian von Einem, Volker Heinemann, Ludwig Fischer von Weikersthal et al. · Journal of Cancer Research and Clinical Oncology
Open access |
9 May 2014 |
114 |
| 10 |
Trastuzumab in combination with 5‐fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2‐positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group
Ralf‐Dieter Hofheinz, Susanne Hegewisch-Becker, Volker Kunzmann et al. · International Journal of Cancer
Open access |
21 May 2021 |
107 |
| 11 |
Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer—central evaluation of FIRE-3
Dominik Paul Modest, Timm Denecke, Johann Pratschke et al. · European Journal of Cancer
|
28 Nov 2017 |
91 |
| 12 |
Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy—final results of the larynx organ preservation trial DeLOS-II
Andreas Dietz et al. · Annals of Oncology
Open access |
22 Aug 2018 |
84 |
| 13 |
Independent Radiological Evaluation of Objective Response, Early Tumor Shrinkage, and Depth of Response in Fire-3 (Aio Krk-0306) in the Final Ras Evaluable Population
Sebastian Stintzing, Dominik Paul Modest, Ludwig Fischer von Weikersthal et al. · Annals of Oncology
Open access |
Sep 2014 |
63 |
| 14 |
Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the ‘Arbeitsgemeinschaft Internistische Onkologie’
Michael Haas, Jens Thomas Siveke, Michael Schenk et al. · European Journal of Cancer
|
20 Mar 2018 |
54 |
| 15 |
Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study—XELAVIRI (AIO KRK0110)
Dominik Paul Modest et al. · Journal of Clinical Oncology
|
2 Nov 2018 |
50 |
| 16 |
Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306)
Dominik Paul Modest, Sebastian Stintzing, Ludwig Fischer von Weikersthal et al. · Oncotarget
Open access |
11 Nov 2017 |
49 |
| 17 |
Study protocol of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with Oxaliplatin and 5-fluorouracil/Folinic acid followed by curative surgical resection in patients with hepatic Oligometastatic adenocarcinoma of the pancreas (HOLIPANC)
Florian Gebauer, Alexander Ioannis Damanakis, Felix Popp et al. · BMC Cancer
Open access |
18 Nov 2021 |
42 |
| 18 |
Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)
Ingo Hartlapp et al. · ESMO Open
Open access |
Aug 2022 |
41 |
| 19 |
Conversion rate in locally advanced pancreatic cancer (LAPC) after nab-paclitaxel/gemcitabine- or FOLFIRINOX-based induction chemotherapy (NEOLAP): Final results of a multicenter randomised phase II AIO trial
Volker Kunzmann, Hana Algül, Eray Goekkurt et al. · Annals of Oncology
Open access |
Oct 2019 |
39 |
| 20 |
Influence of m RNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5‐ FU/LV plus irinotecan or irinotecan plus oxaliplatin as first‐line treatment ( FIRE 1‐trial)
Arndt Stahler, Volker Heinemann, C. Giessen‐Jung et al. · International Journal of Cancer
Open access |
18 Aug 2015 |
37 |
| 21 |
Efficacy of nab-paclitaxel does not seem to be associated with SPARC expression in metastatic breast cancer.
Andreas Schneeweiß, Julia Seitz, Katharina Smetanay et al. · PubMed
|
Nov 2014 |
35 |
| 22 |
Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the ‘burden of therapy’ method
Michael Haas et al. · European Journal of Cancer
|
15 Feb 2021 |
34 |
| 23 |
Epilepsy outcomes in elderly treated with topiramate
Hermann Stefan, Ludwig J. Hubbertz, Ines Peglau et al. · Acta Neurologica Scandinavica
|
31 Mar 2008 |
31 |
| 24 |
Independent Radiological Evaluation of Objective Response Early Tumor Shrinkage, and Depth of Response in FIRE-3 (AIO KRK-0306)
Volker Heinemann, Dominik Paul Modest, Ludwig Fischer von Weikersthal et al. · Annals of Oncology
Open access |
Jun 2014 |
28 |
| 25 |
Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306)
Julian Walter Holch, Swantje Held, Sebastian Stintzing et al. · Annals of Oncology
Open access |
2020 |
27 |
| 26 |
Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials
Arndt Stahler, Sebastian Stintzing, Dominik Paul Modest et al. · Clinical Cancer Research
|
17 Sep 2020 |
25 |
| 27 |
mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer m(CRC): A randomized phase II VOLFI trial of the AIO (AIO-KRK0109)
Michael Geißler, U.M. Martens, R. Knorrenschield et al. · Annals of Oncology
Open access |
Sep 2017 |
24 |
| 28 |
Factors That Influence Conversion to Resectability and Survival After Resection of Metastases in RAS WT Metastatic Colorectal Cancer (mCRC): Analysis of FIRE-3- AIOKRK0306
Dominik Paul Modest, Volker Heinemann, Gunnar Folprecht et al. · Annals of Surgical Oncology
Open access |
14 Mar 2020 |
23 |
| 29 |
Baseline Liquid Biopsy in Relation to Tissue-Based Parameters in Metastatic Colorectal Cancer: Results From the Randomized FIRE-4 (AIO-KRK-0114) Study
Sebastian Stintzing et al. · Journal of Clinical Oncology
|
4 Feb 2025 |
20 |
| 30 |
Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa Phase II Trial, AIO KRK 0212)
Arndt Stahler, Andreas Jay Kind, Christine Sers et al. · Clinical Cancer Research
Open access |
30 Jan 2024 |
19 |
| 31 |
Relation of early tumor shrinkage (ETS) observed in first‐line treatment to efficacy parameters of subsequent treatment in FIRE‐3 (AIOKRK0306)
Dominik Paul Modest et al. · International Journal of Cancer
Open access |
29 Dec 2016 |
19 |
| 32 |
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3
Laura Elisabeth Fischer et al. · British Journal of Cancer
Open access |
30 May 2022 |
18 |
| 33 |
Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa, AIO KRK 0212)
Arndt Stahler et al. · Journal of Clinical Oncology
|
5 Apr 2023 |
17 |
| 34 |
Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110)
Kathrin S. Heinrich, Dominik Paul Modest, Ingrid Ricard et al. · European Journal of Cancer
Open access |
27 Feb 2021 |
16 |
| 35 |
Randomized Phase III Trial of Docetaxel Plus Carboplatin with or without Levofloxacin Prophylaxis in Elderly Patients with Advanced Non-small Cell Lung Cancer: The APRONTA Trial
Wolfgang Schuette, Sylke Nagel, Ludwig Fischer von Weikersthal et al. · Journal of Thoracic Oncology
Open access |
3 Nov 2011 |
15 |
| 36 |
Conversion from valproic acid onto topiramate in adolescents and adults with epilepsy
Andreas Schreiner, Kirsten Stollhoff, W. Ossig et al. · Acta Neurologica Scandinavica
|
2009 |
15 |
| 37 |
A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic Low-Dose Chemotherapy with Single-Agent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung)
Daniel Heudobler, Christian Klaus Jochen Schulz, Jürgen R. Fischer et al. · Frontiers in Pharmacology
Open access |
16 Mar 2021 |
14 |
| 38 |
Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial
Klara Dorman, Stefan Hubert Boeck, Karel Caca et al. · The Lancet. Gastroenterology & hepatology
|
16 Aug 2024 |
12 |
| 39 |
Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer – Results of a phase 1b clinical trial
Danmei Zhang, Christoph Benedikt Westphalen, Michael Quante et al. · European Journal of Cancer
Open access |
15 Feb 2024 |
12 |
| 40 |
Evaluation of circulating tumor DNA as a prognostic and predictive biomarker in BRAF V600E mutated colorectal cancer—results from the FIRE ‐4.5 study
Susanne Klein‐Scory, Alexander Baraniskin, Wolff Schmiegel et al. · Molecular Oncology
Open access |
4 Dec 2024 |
11 |
| 41 |
Evaluation of the inflammation-based modified Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving first-line chemotherapy: a post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110)
Myrto A Boukovala et al. · ESMO Open
Open access |
May 2024 |
11 |
| 42 |
Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212)
Kathrin S. Heinrich, Meinolf Karthaus, Stefan Fruehauf et al. · ESMO Open
Open access |
11 Jul 2023 |
11 |
| 43 |
Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: a prespecified secondary analysis of the PanaMa (AIO KRK 0212) trial
Alexej Ballhausen, Meinolf Karthaus, Stefan Früehauf et al. · European Journal of Cancer
Open access |
28 Jun 2023 |
11 |
| 44 |
FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases – The PARLIM trial (AIO KRK 0314)
Dominik Paul Modest, Meinolf Karthaus, Stefan Kasper et al. · European Journal of Cancer
|
12 Aug 2022 |
11 |
| 45 |
Conversion from carbamazepine or oxcarbazepine to topiramate in adolescents and adults with epilepsy
A. Kowalik, W. Rimpau, H. K. Adam et al. · Acta Neurologica Scandinavica
|
31 Jan 2008 |
11 |
| 46 |
Impact of primary tumor sidedness and sex on prognosis and anti-epidermal growth factor receptor antibody efficacy in BRAF-mutant metastatic colorectal cancer: a pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI
Annabel Helga Sophie Alig, Dominik Paul Modest, Sebastian Stintzing et al. · ESMO Open
Open access |
23 Aug 2024 |
10 |
| 47 |
Kinetics of Renal Function during Induction in Newly Diagnosed Multiple Myeloma: Results of Two Prospective Studies by the German Myeloma Study Group DSMM
Friederike Bachmann et al. · Cancers
Open access |
16 Mar 2021 |
10 |
| 48 |
Lenalidomide, adriamycin, dexamethasone for induction followed by stem-cell transplant in newly diagnosed myeloma
Stefan Tobias Knop et al. · Leukemia
|
25 Apr 2017 |
10 |
| 49 |
Predictive value of computed tomography on surgical resectability in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: Results from a prospective, multicentre phase 2 trial (NEOLAP-AIO-PAK-0113)
KV. Guggenberger, TA. Bley, Swantje Held et al. · European Journal of Radiology
|
10 Apr 2023 |
8 |
| 50 |
Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial)
Arndt Stahler, Volker Heinemann, Veronika Schuster et al. · European Journal of Cancer
|
8 Sep 2021 |
8 |